mynth
← DATABASE
06/2026

OTTOBOCK HUMAN MOBILITY acquired by DHCARE

GERMANY Life Sciences / Medical Devices REV 50M - 100M EUR

Context

DHCare has entered into an agreement to acquire Ottobock's Human Mobility business, which specializes in manual and power wheelchairs, as well as pediatric mobility solutions. This transaction is part of Ottobock's strategy to refocus its resources on its core, high-growth businesses, including prosthetics, neuro-orthotics, and exoskeletons. The divested business generates approximately €80 million in annual revenue, employs around 270 staff members, and comprises the German Human Mobility companies, as well as veldink4Kids, a Dutch specialist in pediatric wheelchairs. For DHCare, this acquisition represents a major strategic milestone and its first since the group's reorganization under its new shareholder structure. The deal significantly expands DHCare's mobility solutions portfolio and strengthens its presence in several key European markets, particularly in the DACH region, where Human Mobility has a long-standing strong position. By combining their expertise, DHCare and Human Mobility aim to create a pan-European platform that can offer an expanded range of clinical solutions, technical services, and after-sales support to patients, healthcare professionals, and payers. The transaction is expected to be completed in the second half of 2026.

OTTOBOCK HUMAN MOBILITY, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Human Mobility is Ottobock's dedicated business unit for wheelchairs and mobility solutions. The company designs, manufactures, and markets a comprehensive range of equipment aimed at enhancing the independence and quality of life of individuals with permanent or temporary functional limitations. Its portfolio includes manual and power wheelchairs, specialized seating systems, rehabilitation strollers, and pediatric mobility solutions for children with complex needs. The company has particular expertise in high-end motorized wheelchairs and customized devices designed to address demanding clinical situations. Headquartered in Germany with complementary activities in the Netherlands through veldink4Kids, Human Mobility has a strong presence in German-speaking countries and a solid reputation among specialized healthcare professionals in rehabilitation, neurology, and orthopedics. Its business model is built on close collaboration with therapists, rehabilitation centers, specialized distributors, and reimbursement agencies to provide tailored solutions that meet the specific needs of users.

Ent. Value

LOGIN

Equity Value

LOGIN

Multiples

EV / Revenue

LOGIN

EV / EBITDA

LOGIN

EV / EBIT

LOGIN

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2025
LOGIN
LOGIN
LOGIN
2024
LOGIN
LOGIN
LOGIN

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
DateAcquirerTargetCountrySectorDeal Context
06/2026CORDENPHARMAAMBIOPHARMUNITED STATESLife Sciences

CordenPharma, backed by private equity firm Astorg, entered into an agreement to acquire AmbioPharm, a US-based CDMO specializing in complex peptide APIs with manufacturing sites in the United States and China

06/2026BRIDGEPOINTOBAGI MEDICALUNITED STATESLife Sciences

Obagi Medical, a medical-grade skincare company positioned in the professional dermatology and aesthetics segment, is being acquired by Bridgepoint as part of a broader consolidation trend across clinical skincare markets

06/2026COLUMBUS VENTURE PARTNERS / MERIEUX EQUITY PARTNERSONA THERAPEUTICSSPAINLife Sciences

The closing of this oversubscribed 86.6 million dollar Series B financing represents a structural capitalization event designed to transition Ona Therapeutics into a clinical-stage oncology platform and fund operations through its primary clinical data readouts

06/20263ILABORATOIRE NUTERGIAFRANCELife Sciences

The acquisition of a 51% controlling interest in Laboratoire Nutergia by 3i presents a primary leveraged buyout transaction designed to transition a mature, founder-led enterprise into an institutionalized platform capable of capturing pan-European market share

06/2026MOTION EQUITY PARTNERSPOLARISFRANCELife Sciences

Motion Equity Partners has acquired a majority stake in Polaris, a leading manufacturer of omega-3 concentrates, from Demea Agro, which had invested in the company three years ago. This transaction is part of a broader strategy to drive external growth and international expansion, with ambitious plans to establish a US-based industrial site and double in size within the next five years

05/2026STRYKERAMPLITUDE VASCULAR SYSTEMSUNITED STATESLife Sciences

Stryker has completed the acquisition of Amplitude Vascular Systems, a private medical device company, which develops a next-generation intravascular lithotripsy (IVL) platform, designed to treat complex peripheral arterial disease, this acquisition represents a significant milestone in the expansion of Stryker's peripheral vascular portfolio, by integrating Amplitude Vascular Systems' innovative technology, which uses carbon dioxide-generated pressure waves, to optimize arterial diameter, while minimizing damage and improving deliverability, treatment speed, and therapeutic efficacy, with the goal of strengthening Stryker's position in peripheral vascular solutions, by offering solutions for physicians and patients, to treat cardiovascular disease, Stryker's strategy is to develop its portfolio of products and services, to improve patient and healthcare outcomes, by offering innovative and integrated solutions, for physicians, hospitals, and patients, financial and legal advisory services were provided by reputable consulting firms, to ensure the success of the operation

04/2026FINE FOODS & PHARMACEUTICALSSOFARITALYLife Sciences

The group has finalized a binding agreement to acquire the total share capital of the target from Alfasigma S.p.A., a maneuver designed to fundamentally expand its specialized manufacturing capabilities

04/2026VITREX MEDICAL GROUPHERNIAMESHITALYLife Sciences

Vitrex Medical Group (VMG) has finalized the acquisition of a majority stake in Herniamesh, an operation designed to fundamentally accelerate the group's transformation into a global leader in surgical technology

04/2026AMERICAN INDUSTRIAL PARTNERS AIPAVANOS MEDICALUNITED STATESLife Sciences

American Industrial Partners has finalized a definitive agreement to acquire Avanos Medical in an all-cash transaction, a maneuver designed to fundamentally reinforce the target's competitive positioning in the specialized medical technology arena

04/2026REVENIO GROUP CORPORATIONVISIONIX INTERNATIONALFRANCELife Sciences

The group has finalized a definitive agreement to acquire the entire share capital of the target, a maneuver designed to fundamentally expand its presence as a turnkey provider in the global eye care market

REFERENCES

Revenue range: 50M - 100M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of OTTOBOCK HUMAN MOBILITY by DHCARE are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: dhcare